Will Weakness in Micro-Tech (Nanjing) Co.,Ltd's (SHSE:688029) Stock Prove Temporary Given Strong Fundamentals?
Will Weakness in Micro-Tech (Nanjing) Co.,Ltd's (SHSE:688029) Stock Prove Temporary Given Strong Fundamentals?
It is hard to get excited after looking at Micro-Tech (Nanjing)Ltd's (SHSE:688029) recent performance, when its stock has declined 15% over the past three months. However, stock prices are usually driven by a company's financial performance over the long term, which in this case looks quite promising. In this article, we decided to focus on Micro-Tech (Nanjing)Ltd's ROE.
在看到南微醫學(南京)股份有限公司(SHSE:688029)近三個月股價下跌15%後,很難感到興奮。然而,股票價格通常受到公司長期財務表現的影響,在這種情況下,前景看起來相當有希望。在本文中,我們決定專注於南微醫學(南京)股份有限公司的roe。
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
股東要考慮的關鍵因素之一是淨資產收益率或roe,因爲它告訴他們公司如何有效地重新投資他們的資本。簡單點說,它衡量了公司與股東權益相關的盈利能力。
How Is ROE Calculated?
淨資產收益率怎麼計算?
The formula for ROE is:
roe的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益
So, based on the above formula, the ROE for Micro-Tech (Nanjing)Ltd is:
因此,基於上述公式,南微醫學(南京)有限公司的roe爲:
14% = CN¥544m ÷ CN¥3.8b (Based on the trailing twelve months to June 2024).
14% = CN¥54400萬 ÷ CN¥38億(基於截至2024年6月的過去十二個月)。
The 'return' is the amount earned after tax over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.14.
「回報」是稅後收益在過去十二個月內賺取的金額。因此,這意味着對於每個股東的1元人民幣投資,該公司可以創造0.14元人民幣的利潤。
What Has ROE Got To Do With Earnings Growth?
roe與盈利增長有何關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
我們已經確定ROE作爲評估公司未來收益的有效指標。現在我們需要評估公司爲未來增長所保留的利潤量,從而給我們一個關於公司增長潛力的想法。假設其他條件都相同,既具有較高ROE又具有較高利潤保留的公司通常是增長率更高的公司,相比之下沒有這些特點的公司會更低。
A Side By Side comparison of Micro-Tech (Nanjing)Ltd's Earnings Growth And 14% ROE
南微醫學(南京)有限公司的盈利增長和14% roe的較旁邊的對比
To begin with, Micro-Tech (Nanjing)Ltd seems to have a respectable ROE. Further, the company's ROE compares quite favorably to the industry average of 7.2%. Probably as a result of this, Micro-Tech (Nanjing)Ltd was able to see a decent growth of 16% over the last five years.
首先,南微醫學(南京)有限公司的roe似乎還不錯。此外,該公司的roe與行業平均水平相比較有優勢。可能正是由於此原因,南微醫學(南京)有限公司在過去五年間實現了16%的不錯增長。
We then compared Micro-Tech (Nanjing)Ltd's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 5.2% in the same 5-year period.
接下來,我們將南微醫學(南京)有限公司的淨利潤增長與行業進行了比較,並很高興地看到,該公司的增長數據較高,而行業在同一5年期間的增長率爲5.2%。
![1724544905181](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240825/42828559-0-46f516c3ab9e769d3f56e7cc568be670.webp/bigjpg)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Micro-Tech (Nanjing)Ltd is trading on a high P/E or a low P/E, relative to its industry.
給一家公司附加價值的基礎很大程度上與其盈利增長相關。投資者接下來需要確定的是,預期的盈利增長是否已經融入了股價之中。這樣做將有助於他們判斷股票的未來前景是光明還是不樂觀。預期盈利增長的一個很好指標是市盈率,它根據公司的盈利前景確定市場願意爲一隻股票支付的價格。因此,您可能想要查看Micro-Tech(南微醫學醫療)Ltd的市盈率是高還是低,相對於其所在行業。
Is Micro-Tech (Nanjing)Ltd Efficiently Re-investing Its Profits?
Micro-Tech(南微醫學醫療)Ltd是否高效地重新投資其利潤?
Micro-Tech (Nanjing)Ltd has a healthy combination of a moderate three-year median payout ratio of 31% (or a retention ratio of 69%) and a respectable amount of growth in earnings as we saw above, meaning that the company has been making efficient use of its profits.
Micro-Tech(南微醫學醫療)Ltd在盈利方面有一個健康的組合,三年的中位數派息比率爲31%(或留存比率爲69%),並且盈利增長相對可觀,這意味着該公司一直在有效利用其利潤。
Besides, Micro-Tech (Nanjing)Ltd has been paying dividends over a period of four years. This shows that the company is committed to sharing profits with its shareholders.
此外,Micro-Tech(南微醫學醫療)Ltd連續四年支付股息。這表明該公司致力於與股東分享利潤。
Summary
總的來說,我們對偉明環保的表現非常滿意。具體而言,我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然,這導致公司的收益大幅增長。但是,最新的行業分析師預測表明,該公司的收益預計將加速增長。
In total, we are pretty happy with Micro-Tech (Nanjing)Ltd's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
總體來說,我們對南京南微醫學有限公司的表現非常滿意。具體來說,我們喜歡該公司以高回報率重新投資其巨額利潤,這當然導致了該公司收益的大幅增長。然而,最新的行業分析師預測顯示,該公司的收益預計將加速增長。要了解更多關於該公司未來收益增長預測的信息,請查閱這份關於該公司的分析師預測的免費報告。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。